Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 30-Apr 2022. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5035170010 | Tenofovir disoproxil phosphate (substance) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 5035171014 | Tenofovir disoproxil phosphate | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Tenofovir disoproxil phosphate (substance) | Is a | Reverse transcriptase inhibitor | true | Inferred relationship | Some | ||
| Tenofovir disoproxil phosphate (substance) | Is a | Carboxylic ester (substance) | true | Inferred relationship | Some | ||
| Tenofovir disoproxil phosphate (substance) | Has disposition (attribute) | Reverse transcriptase inhibitor (disposition) | true | Inferred relationship | Some | ||
| Tenofovir disoproxil phosphate (substance) | Is modification of (attribute) | Tenofovir disoproxil (substance) | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil (as tenofovir disoproxil phosphate) 245 mg oral tablet | Has precise active ingredient | True | Tenofovir disoproxil phosphate (substance) | Inferred relationship | Some | 3 |
| Product containing precisely tenofovir disoproxil (as tenofovir disoproxil phosphate) 245 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | True | Tenofovir disoproxil phosphate (substance) | Inferred relationship | Some | 1 |
This concept is not in any reference sets
FHIR